California
Association
for
Medical Laboratory Technology
Distance Learning Program
|
Megaloblastic
Anemia Course
Number: DL-975 © California Association
for Medical Laboratory Technology. CAMLT is approved by the California Department
of Health Services 1895 Mowry Ave, Suite 112 Notification of Distance Learning Deadline This is a reminder that all the continuing education units required to renew your license must be earned no later than the expiration date printed on your license. If some of your units are made up of Distance Learning courses, please allow yourself enough time to retake the test in the event you do not pass on the first attempt. CAMLT urges you to earn your CE units early! |
| This course is configured to be completed on-line. You can register
for the course, submit secure payment using a credit card via PayPal,
take the quiz on-line and receive your graded score.
If you pass, your certificate will be mailed to you from
the CAMLT office. If you fail, you must submit new payment and obtain a new PayPal receipt each time you take the test. A certificate will be issued only if you have paid for re-taking the course and you pass the test. If you want to submit your registration and quiz via fax or mail you should print the Adobe Acrobat version of the course which includes the required Registration/Quiz form. |
| Links to: On-line REGISTRATION, PAYMENT and QUIZ Printable Acrobat version of this course * Review Questions at the end of this Course Other Distance Learning Courses |
|
Megaloblastic Anemia
OBJECTIVES:| CBC: | Patient | Normal |
| RBC | 1.14 x 106/l | 4.7-6.1 x 106/l |
| WBC | 3.6 x 103/l | 4.8-10.9 x 103/l |
| Hematocrit | 12.7% | 42-52% |
| Hemoglobin | 4.4 g/dl | 14-18 g/dl |
| MCV | 111.4 fl | 80-94 fl |
| MCH | 38.7 pg | 27-31 pg |
| MCHC | 34.7 g/dl | 33-37 g/dl |
| RDW | 22.1% | 11.5-14.5% |
| Platelets | 76 x 103/l | 130-400 x 103/l |
| MPV | 9.3 fl | 7.4-10.4 fl |
| Differential: | Patient | Normal |
| PMN | 29% | 39-68% |
| Bands |
1 | 2-10 |
| Lymphs | 67 | 16-45 |
| Monos | 3 | 3-14 |
| NRBCs/100 wbc | 2 | 0 |
| Suspect flags: | dimorphic RBC: microcytic RBC, RBC fragments | |
| Definitive flags: | neutropenia, lymphocytosis, 2+ anisocytosis, 3+ macrocytosis, thrombocytopenia | |
| Reticulocyte count: | Patient | Normal |
| Reticulocytes | 2.6% | 0.5-1.5% |
| Retic, Absolute | 29.0 x 103/l | 22.5-88.5 x 103/l |
| Retic, Corrected | 0.7% | 0.4-1.7% |
| B12/Folate Studies: | Patient | Normal |
| B12 | <100 pg/ml | 200-950 pg/ml |
| Folate | 12.7 ng/ml | 3.7-19.0 ng/ml |
INTRODUCTION:
Megaloblastic anemias are a heterogeneous group of disorders that have common
blood abnormalities and symptoms. The characteristic blood picture consists
of large oval erythrocytes, hypersegmented neutrophils and large abnormal platelets.
Bone marrow RBC precursors show abnormally high nuclear to cytoplasmic ratio
and abnormal megakaryocytes. Nuclear maturation is delayed while cytoplasmic
development is normal.
The diseases associated with megaloblastosis are primarily pernicious anemia
(associated with vitamin B12 deficiency) and folic acid deficiency. Although
the number of megaloblastic anemia cases has decreased in recent years, the
incidence remains between 0.25-0.5 cases per 1000 in older individuals.
HISTORY:
Paul Ehrlich in 1880 first used the term megaloblast to describe the abnormal
cells in the bone marrow of a patient with pernicious anemia. He felt the very
large basophilic RBC precursor was a cell type unique to the disease. We now
know that this cell is a morphologically and functionally abnormal counterpart
of the normal erythroid precursor cell.
Thomas Addison first described pernicious anemia, the best known of the megaloblastic
anemias, in 1855. For a number of years the disease was known as Addisonian
anemia. Anton Biermer in 1872 first used the term, pernicious anemia.
Treatment for pernicious anemia was instituted in 1926 when it was found that
giving patients large amounts of liver reversed the disease process. The active
liver principle, vitamin B12, was discovered in 1948 but it took 25 years to
develop a synthetic vitamin B12.
BIOCHEMICAL BASIS OF MEGALOBLASTIC ANEMIAS:
The etiology of the megaloblastic anemias is impaired DNA synthesis
and assembly. The most common causes are vitamin B12 (cobalamin) or folic acid
deficiencies. These substances are essential in the DNA synthesis pathway. Impaired
DNA production causes disruption of cell division and maturation. Rapidly proliferating
cells of the bone marrow and epithelial surfaces are primarily affected, leading
to the characteristic blood picture and symptoms. Cobalamin is also necessary
for normal function of cells of the nervous system.
Cobalamin and folate metabolisms are related and deficiency of
either results in the deoxyuridylate–deoxythymidylate pathway impairment
(see Figure 1). This pathway forms deoxythymidylate from deoxyuridylate and
methionine from homocysteine. Folic acid is required for synthesis of thymidylate.
Since thymidylate is the precursor to thymine, essential for DNA, a limitation
in the supply of thymidylate impairs DNA synthesis and leads to the morphologic
manifestation of megaloblastic maturation.
Cobalamin catalyzes the conversion of homocysteine to methionine.
When this reaction is impaired, folate metabolism is deranged. Since folic acid
is required for synthesis of thymidylate, this derangement underlies the defect
in DNA synthesis and the megaloblastic maturation in patients who are cobalamin
deficient. Impairment in the conversion of homocysteine to methionine may also
be partly responsible for the neurologic complications of cobalamin deficiency.
Methionine is needed for the production of choline and choline-containing phospholipids,
which are required in the nervous system.

Folic acid: This is the common name for pteroylmonoglutamic acid. It is formed of three basic components: a pteridine derivative, para-aminobenzoic acid and L-glutamic acid. Many different plants and bacteria synthesize it. Fruits and vegetables form the primary dietary source of the compound but prolonged cooking destroys it. The minimum daily requirement is about 50 µg but this may be increased several-fold during times of increased metabolic demand such as pregnancy or in hemolytic anemias. Normally body stores range from 5 to 20 mg, with half stored in the liver. The large minimum daily requirement means that a deficiency will occur within months if dietary intake or intestinal absorption is curtailed. It is readily absorbed in the duodenum and proximal jejunum.
SYMPTOMS OF MEGALOBLASTIC ANEMIA:
The anemia symptoms of both folic acid deficiency and vitamin B12 deficiency
are the same. In both there are often gastrointestinal tract symptoms such as
anorexia and diarrhea because the epithelial cells lining the intestines also
have a rapid turnover. Frequently the patient does not seek medical help until
some of the following conditions occur: weakness, light-headedness, palpitations,
angina, and symptoms of congenital heart failure. Folic acid deficiency results
in anemia and intestinal manifestations but not neurological symptoms.
In pernicious anemia neurologic manifestations also occur. The onset is insidious
as destruction of parietal cells increases and the body stores of vitamin B12
are gradually consumed. Neurologic symptoms begin after demyelination followed
by axonal degeneration. The most common manifestations are numbness and parasthesias
in the extremities, weakness and ataxia. The patient experiences tingling of
the extremities and has an unsteady gait. Some have deranged mental states ranging
from irritability and forgetfulness to severe dementia and psychosis. Although
administering vitamin B12 by injection may cure the anemia, the neurologic symptoms
may persist if there has been death of neurons. Differentiation between folic
acid deficiency and vitamin B12 deficiency is important. If large amounts of
folic acid are given to a pernicious anemia patient, the anemia may be improved
but the neurologic symptoms become worse.
DEFICIENCY STATES: (See Table I, Classification of Deficiency
States)
Causes of megaloblastic anemia differ in various parts of the world.
In the temperate zones folate deficiency in alcoholics and pernicious anemia
predominate. In the equatorial areas tropical sprue is an important cause. In
Scandinavia the fish tapeworm, Diphyllobothrium latum, may contribute
to the incidence.
In the United States, supplementation of bread and cereal products with folic
acid and vitamin B12 has decreased the incidence of megaloblastic anemia due
to inadequate intake. Only people with very poor diets, such as alcoholics who
get most of their calories from drinks, have inadequate intake of folic acid.
Defective absorption, increased folic acid requirements and use of drugs that
impair DNA metabolism continue to cause megaloblastosis in the U.S.
Cobalamin (Vitamin B12) Deficiency:
Deficiency of vitamin B12 in the U.S. is almost always due to malabsorption.
Several different conditions may cause malabsorption—decreased production
of Intrinsic Factor (IF) (pernicious anemia), disorders of the terminal ileum,
and competition in the intestinal tract for vitamin B12.
Pernicious Anemia:
This disease is caused by inadequate secretion of IF by the parietal cells in
the stomach—due to atrophy of the gastric mucosa or autoimmune destruction
of the parietal cells. It is found most often in older individuals, particularly
in those of northern European descent or in African Americans. It is less common
in southern Europeans and Asians. There is an increased incidence of pernicious
anemia in patients with autoimmune diseases such as Hashimoto’s thyroiditis,
Grave’s Disease, myxedema, or hypoparathyroidism. About 90% of pernicious
anemia patients have abnormal circulating antibodies against parietal cells.
About 60% have anti-intrinsic factor antibodies. Relatives of pernicious anemia
patients have increased incidence of the disease.
Disorders of the terminal ileum:
Any abnormality that compromises the absorptive capacity of the terminal ileum
can result in cobalamin deficiency. The conditions include ileitis, surgical
resection of the small intestine and sprue.
Competition for Vitamin B12 by intestinal organisms:
D. latum, the fish tapeworm, may cause vitamin B12 deficiency
by competition for vitamin B12 in the intestinal tract. Elimination of the parasite
cures the problem.
Blind loops and other intestinal anatomic lesions may harbor bacteria that consume
cobalamin before absorption.
Folic Acid Deficiency:
Folic acid deficiency can be due to dietary deficiency, increased requirement,
or defective absorption.
Dietary deficiency:
Dietary supplementation has decreased the incidence of dietary deficiency since
the required addition of folic acid to enriched grain products was instituted
in 1998. However, it can still occur in individuals with markedly inadequate
diets such as alcoholics and the elderly who eat no fresh food.
Increased demand:
Pregnant women, hemolytic anemia patients, and some infants and teenagers undergoing
growth spurts have increased demand for folic acid. Folic acid deficiency in
the first weeks of pregnancy, usually before the pregnancy is known, can cause
neural tube defects in the fetus. Dietary supplementation has decreased the
incidence of this defect by 50%. Patients with markedly increased hematopoiesis
as occurs in hemolytic anemias require additional folic acid.
Defective absorption:
Tropical sprue, a poorly understood disease with malabsorption, and non-tropical
(celiac) sprue (gluten sensitivity) may result in decreased absorption of folic
acid. Other small bowel disorders may also cause malabsorption.
Other causes of Deficiency States:
Drugs that impair DNA synthesis or metabolism may cause megaloblastic anemia.
These are primarily drugs used in the treatment of malignancies, particularly
leukemias, including DNA inhibitors (purine and pyrimidine analogues) and folate
antagonists (methotrexate). Zidovudine, an anti-viral drug used in HIV treatment,
may also cause megaloblastic anemia.
TABLE I: CLASSIFICATION OF DEFICIENCY STATES:
Cobalamin Deficiency:
Inadequate intake (vegans—strict vegetarians)
Defective absorption
Inadequate production of intrinsic factor
Pernicious anemia
Gastrectomy
Congenital absence or abnormality
of intrinsic factor
Disorders of terminal ileum
Tropical sprue
Non-tropical sprue
Ileal resection
Regional enteritis
Neoplasms of ileum
Competition for Cobalamin
Fish tapeworm (Diphyllobothrium
latum)
Bacteria (blind loop syndrome)
Drugs: para amino salicylic acid, colchicines,
neomycin
Impaired utilization of cobalamin
Nitrous oxide
Inborn errors of metabolism (rare)
Folic Acid Deficiency
Inadequate intake
Increased requirements
Pregnancy
Infancy
Malignancy
Increased hematopoiesis (hemolytic anemias)
Defective absorption
Intestinal disorders (Tropical sprue, Non-tropical
sprue)
Drugs: phenytoin, barbiturates, alcohol
Impaired metabolism
Folic acid antagonist therapy (methotrexate, trimethoprim,
pyrimethamine)
Enzyme deficiencies
Other:
Drugs that impair DNA metabolism
Purine and pyrimidine antagonists, acyclovir, zidovudine,
hydroxyurea
Marrow stem cell disorders
Dysmyelopoietic syndromes
Erythroeukemia (DiGuglielmo’s syndrome)
Metabolic disorders (rare)
LABORATORY TESTS:
The finding of significant macrocytosis (MCV>100 fL) suggests
the presence of a megaloblastic anemia. Other causes of macrocytes are hemolysis
with increased reticulocytes, liver disease, alcoholism, hypothyroidism, and
aplastic anemia; however, the macrocytes in these conditions are round, not
oval. If the MCV is over 110 fL, the patient is most likely to have a megaloblastic
anemia. Other findings in the blood count are decreased hemoglobin and RBC count,
decreased numbers of WBC and platelets.
The blood smear characteristically shows well-hemoglobinized oval macrocytes
and aniso-poikilocytosis. Occasional nucleated RBC may be present. The neutrophils
may show hypersegmentation. The finding of one neutrophil with 6 lobes signifies
megaloblastic anemia (normal neutrophils have 2-4 lobes). Large or bizarre misshapen
platelets are usually present.
Bone marrow shows hypercellularity with decreased myeloid:erythroid ratio. The
erythroid precursors are abnormally large with the nucleus less mature than
the cytoplasm. The nuclear chromatin is more dispersed than normal and shows
a characteristic megaloblastic pattern. Granulocyte precursors are larger than
normal, particularly bands and metamyelocytes. Megakaryocytes are decreased
with abnormal morphology.
Erythroid precursors show increased destruction (ineffective erythropoiesis).
This increased destruction results in increased unconjugated bilirubin and lactic
acid dehydrogenase in the plasma. The patient may show jaundice from the bilirubin.
The reticulocyte count helps differentiate between other causes of macrocytosis
and megaloblastosis. If the reticulocyte count is sufficiently increased to
be the cause of macrocytosis, a possible hemolytic anemia needs to be investigated.
Reticulocytes may show polychromatophilia on the blood smear, and are round,
not oval. If the reticulocyte count is decreased/normal then tests need to be
done to determine which deficiency is present. Serum folic acid and vitamin
B12 levels are performed. If the serum folate is less than the normal range,
this is the cause of the megaloblastic anemia. If the serum cobalamin level
is decreased below 100pg/ml, then further tests need to be done to find the
cause. The Schilling test can determine whether the cause is pernicious anemia,
some other cause of defective absorption, or dietary deficiency.
The Schilling test: A patient is given radioactive cobalamin by mouth, followed
shortly thereafter by an intramuscular injection of unlabeled cobalamin. This
unlabeled cobalamin is given to fill the deficient body sites so that absorbed
radioactive B12 will be excreted in the urine rather than be retained to fulfill
the deficiency. The proportion of the administered radioactivity excreted in
the urine during the next 24 hours provides a measure of absorption of cobalamin
(making sure the urine collection is complete). Since vitamin B12 deficiency
is almost always due to deficient absorption, this stage of the Schilling test
should be abnormal, i.e., small amounts of radioactivity in the urine. Next
the patient is given radiolabeled cobalamin bound to intrinsic factor. Absorption
of the radiolabeled B12 bound to intrinsic factor will be normal if the patient
has pernicious anemia. If cobalamin absorption is still decreased, the patient
may have ileal disease or bacterial overgrowth (blind loop) syndrome. Bacterial
overgrowth may be corrected by antibiotic administration. Ileal disease and
pernicious anemia require regular vitamin B12 injections.
CASE STUDY: Refer to the case at the beginning of the article.
The patient’s cell counts reflected a slight pancytopenia.
Inspection of the Coulter printout showed a relatively normal WBC histogram.
(The histograms are not shown in this article).
The RBC histogram showed a very broad, distorted bell-shaped
curve. The mode is shifted to the right, which correlates with the MCV of 111.
The left side of the histogram, which normally comes down to the baseline, showed
a significant population of small cells, which are most probably schistocytes.
The histogram is very wide. This is reflected by the red cell distribution width
(RDW) of 22.1.
The platelet histogram, which usually shows a normal distribution,
does not come down to the baseline on the right side, which correlates with
the presence of schistocytes. These RBC fragments are in the size range of platelets
and are included in the platelet count.
The Definitive and Suspect Flags indicated all of these abnormalities.
On the manual differential, RBC morphology was markedly
abnormal with marked aniso-poikilocytosis including macro-ovalocytes, target
cells, teardrop RBCs and schistocytes. Nucleated RBCs were present. A few hypersegmented
neutrophils were also seen. The reticulocyte % and the absolute reticulocyte
count were slightly elevated and the corrected reticulocyte count was normal,
but inappropriately low for the degree of anemia present.
A vitamin B12 assay was performed which showed the patient to be
markedly deficient. Folate levels were normal.
History: The patient was born in 1977 at 28 weeks gestation, weighing
2 lbs., 7 oz. He had problems with hyaline membrane disease and developed necrotizing
enterocolitis at five days of age. The bowel perforated on the eighth day and
100 cm. of his bowel, including the ileocecal valve, was removed. This was estimated
to be approximately 50% of his ileum.
He was eventually released from the hospital and placed on multi-vitamins
with folate and on vitamin B12 replacement therapy by intramuscular injection.
The family had numerous employment and insurance difficulties during the ensuing
years and the vitamin B12 injections were not given regularly.
A Schilling test (without Intrinsic Factor) had been performed
in 1984, which established that the patient was definitely unable to absorb
vitamin B12 normally, as excretion of radiolabelled Co-58 was less than 0.6%
(normal >7%). The next step of the Schilling test was not done, since the
patient history indicated that a large portion of the ileum had been removed,
thus the remaining area was shown to be unable to absorb the vitamin.
Finally, vitamin B12 injections were discontinued 2-3 years ago
because the family lacked medical insurance and could not afford the treatments.
This time frame correlates with the amount of time necessary to deplete stored
vitamin B12 in a child this age and with the onset of his clinical symptoms.
Case Study Conclusions:
The patient was given an injection of vitamin B12 and re-tested a week later.
There was marked improvement in his clinical symptoms, CBC and a significant
reticulocyte response.
This patient requires ongoing vitamin B12 replacement therapy for the rest of
his life. Failure to comply will result in reappearance of symptoms and possible
irreversible damage to his nervous system.
REFERENCES
1. Case study furnished by Cannon J. UCDavis Medical Center
2. Harmening DM. Clinical Hematology and Fundamentals of Hemostasis.
4th Ed. 2001
3. Braunwald E, et al., eds., Harrison’s principles of Internal Medicine.
15th ed. New York, McGraw-Hill. 2001; 674-680.
4. Schick P, Megaloblastic Anemia. Available at: www.emedicine.com/MED/topic1420.htm
Accessed 2/14/2006
REVIEW QUESTIONS
Course #066-975 - Choose the one best answer
Link to On-line REGISTRATION,
PAYMENT and QUIZ to submit for credit